Update on Therapeutics in Inborn Errors
The Update on Therapeutics in Inborn Errors session will discuss updates and discussion of novel therapies including gene therapy trials and techniques.
This educational activity is supported by an educational grant from Ultragenyx.
Cary Harding, MD
Oregon Health & Science University
Cary Harding, speaker for this activity, is a consultant for BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, Synlogic Therapeutics, Sanofi-Genzyme, Jnana Therapeutics, PTC Therapeutics and American Gene Technologies, and a Data Safety Monitoring Board Member for LogicBio Therapeutics.
Planners, faculty, and others in control of content (either individually or as a group) have no relevant financial relationships with ineligible companies.
All of the relevant financial relationships listed have been mitigated.
Children’s Hospital Colorado is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Children’s Hospital Colorado designates this Live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
A general certificate of attendance will be available after the completion of the online evaluation. Claim only credit commensurate of your conference attendance.
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Attendance